Genome-wide identification and annotation of HIF-1α binding sites in two cell lines using massively parallel sequencing
© Springer Science+Business Media B.V. 2011
Received: 15 November 2010
Accepted: 1 February 2011
Published: 19 February 2011
We identified 531 and 616 putative HIF-1α target sites by ChIP-Seq in the cancerous cell line DLD-1 and the non-cancerous cell line TIG-3, respectively. We also examined the positions and expression levels of transcriptional start sites (TSSs) in these cell lines using our TSS-Seq method. We observed that 121 and 48 genes in DLD-1 and TIG-3 cells, respectively, had HIF-1α binding sites in proximal regions of the previously reported TSSs that were up-regulated at the transcriptional level. In addition, 193 and 123 of the HIF-1α target sites, respectively, were located in proximal regions of previously uncharacterized TSSs, namely, TSSs of putative alternative promoters of protein-coding genes or promoters of putative non-protein-coding transcripts. The hypoxic response of DLD-1 cells was more significant than that of TIG-3 cells with respect to both the number of target sites and the degree of induced changes in transcript expression. The Nucleosome-Seq and ChIP-Seq analyses of histone modifications revealed that the chromatin formed an open structure in regions surrounding the HIF-1α binding sites, but this event occurred prior to the actual binding of HIF-1α. Different cellular histories may be encoded by chromatin structures and determine the activation of specific genes in response to hypoxic shock.
KeywordsHIF-1 alpha Hypoxia ChIP-Seq Transcriptome
Cancer cells in solid tumors are frequently exposed to limited oxygen environments because aberrantly growing cancer cells can cause a shortage of blood flow (Pouyssegur et al. 2006; Harris 2002; Keith and Simon 2007). Hypoxia is a term that is used to describe such cellular environments, which have an oxygen concentration between 0.02 and 3% (Thomas and Johannes 2007). It is important to understand the behavior of cancer cells under hypoxia because hypoxic conditions can be utilized to develop a therapeutic method to treat cancers (Fyles et al. 1998; Nordsmark et al. 1996). If cancer cells were vulnerable to hypoxia, they would lose their ability to survive. In addition, controlling the hypoxic responses of cells may lead to new clinical therapeutics not only for solid tumors (Semenza 2003; Semenza 2010) but also for tissue ischemia and several inflammatory diseases (Fraisl et al. 2009; Semenza 2000).
Tumor cells adapt to hypoxic conditions through modifications of their gene expression patterns. For example, ATP metabolism changes from oxidative phosphorylation to anaerobic glycolysis. During this process, glucose uptake is enhanced, angiogenesis is induced to obtain a sufficient blood supply, and cell migration is promoted (Harris 2002; Pouyssegur et al. 2006; Gatenby and Gillies 2004; Hirota and Semenza 2006; Keith and Simon 2007). The central regulators of these changes in gene expression, which collectively lead to changes in cellular responses, are the transcription factors hypoxia-inducible factors 1 and 2 (HIF-1/2) (Wang and Semenza 1995; Tian et al. 1997). Both HIF-1 and HIF-2 consist of two subunits, HIF-α and HIF-β (or ARNT). The α-subunit (HIF-1α, HIF-2α) is the oxygen-sensitive subunit. Under hypoxic conditions, HIF-1α (or HIF-2α) translocates from the cytoplasm to the nucleus and dimerizes with HIF-β. The HIF heterodimer complex binds to a sequence motif called the hypoxia response element (HRE) and activates the expression of genes that are necessary for cellular survival under hypoxic conditions (Maxwell 2005; Poon et al. 2009). Although HIF-1α demonstrates extensive sequence similarity to HIF-2α and is regulated via the same mechanism, HIF-1 and HIF-2 are assumed to possess distinct biological roles. HIF-2α expression is restricted to particular cell types, whereas HIF-1α is expressed ubiquitously (Wiesener et al. 2003). Additionally, genes encoding glycolytic enzymes such as PGK1 and GLUT1 are unique targets of HIF-1 (Wenger et al. 2005; Raval et al. 2005).
Because of the inferred important roles of HIF-1α, there have been several attempts to comprehensively identify HIF-1α targets (Ortiz-Barahona et al. 2010). Although computational methods alone may still require further innovation due to the ambiguity of the HRE motif, the combination of computational methods and expression analyses using microarrays has proven to be a powerful approach (Benita et al. 2009). More recently, several papers have reported the identification of HIF-1α binding sites based on chromatin immunoprecipitation and microarray (ChIP-chip) technology (Mole et al. 2009; Xia et al. 2009; Xia and Kung 2009). These studies have reported that about 400–500 of the HIF-1α binding sites in the human genome and approximately 70% of the HIF-1α binding sequences contain HREs.
Recent microarray-based approaches have produced far more information regarding HIF-1 targets than have conventional methods. However, these microarray methods have several limitations; namely, they cannot be used to analyze previously uncharacterized genes, for example, intergenic transcripts or transcripts of alternative promoters (Davuluri et al. 2008; Landry et al. 2003). In addition, the resolution of the data does not exceed the intervals of the DNA probes. The recently developed massively parallel sequencing technologies have provided a potential means to improve upon these methods. For example, the Illumina GA sequencer can sequence 200–250 million sequences per run. By utilizing Illumina GA and ChIP technologies (ChIP-Seq), the binding sites of several transcription factors have been reported (Valouev et al. 2008; Robertson et al. 2007; Kwon et al. 2009; Welboren et al. 2009; Park 2009). On the other hand, we also developed a method for sequencing the 5′-ends of mRNAs by combining our oligo-capping technique with the Illumina GA sequencer (Tsuchihara et al. 2009). This method, which we named TSS-Seq, enables us to obtain precise information regarding the positions of the transcriptional start sites (TSSs) together with their expression levels in a high-throughput manner. In our previous report, we applied TSS-seq to observe gene expression changes in response to hypoxia in several cell lines (Tsuchihara et al. 2009).
To identify TSSs with hypoxic responses elicited directly by HIF-1α binding, we performed HIF-1α ChIP analysis and combined the resultant data with the TSS-Seq data. Furthermore, we carried out Illumina GA sequencing analysis using micrococcal nuclease-digested genomic DNA (Nucleosome-Seq) (Albert et al. 2007; Jiang and Pugh 2009; Schones et al. 2008). We examined the changes in nucleosome structure caused by HIF-1α binding and the subsequent transcriptional activation. We also examined the chromatin statuses surrounding the HIF-1α binding sites by ChIP-Seq analysis of RNA polymerase II (pol II) and a series of histone modifications, namely, H3K4 trimethylation (H3K4me3), H3 acetylation (H3Ac) and H3K27 trimethylation (H3K27me3) (Barski et al. 2007). H3K4me3 and H3Ac are known to be characteristic of an open chromatin structure, and H3K27me3 is characteristic of a closed chromatin structure. A colorectal cancer epithelial cell line (DLD-1) and a normal embryonic lung fibroblast cell line (TIG-3) were used for these analyses. Here, we report the genome-wide identification and characterization of HIF-1 targets using several types of massively parallel sequencing analyses. We further compared the observed targets between DLD-1 cells and TIG-3 cells to examine the cellular responses characteristic of these cells.
Materials and methods
The short-read tag sequences used in the present work have been deposited in DDBJ under the following accession numbers: SRA003625 (TSS-Seq data), DRA000007-000008 and DRA000190-000191 (pol II ChIP-Seq data), DRA000073-000075 and DRA000003 (Nucleosome-Seq data), DRA000178-000185 (HIF-1α ChIP-Seq data), DRA000277-000284 (H3K4me3 ChIP-Seq data), DRA000285-000288 and DRA000293-000296 (H3Ac ChIP-Seq data) and DRA000289-000292 and DRA000297-000300 (H3K27me3 ChIP-Seq data).
The data generated in this study are accessible via following URL in BED file format: http://www.dbtss.hgc.jp/cgi-bin/downloader2.cgi/chip.tar.gz (ChIP-Seq data), http://www.dbtss.hgc.jp/cgi-bin/downloader2.cgi/nucleosome_bed.tar.gz (Nucleosome-Seq data), http://www.dbtss.hgc.jp/cgi-bin/downloader2.cgi/rnaseq.tar.gz (RNA-Seq data) and ftp://ftp.hgc.jp/pub/hgc/db/dbtss/dbtss_ver7/bed_files/ (TSS-Seq data).
The human colorectal cancer cell line DLD-1 (Japan Health Science Research Resources Bank cell number JCRB9094) was maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Nissui) Supplemented with 10% fetal calf serum, 4.5 g/l glucose, and antibiotics. The human normal embryonic lung fibroblast cell line TIG-3 (Japan Health Science Research Resources Bank cell number JCRB0506) was maintained in MEM (GIBCO) Supplemented with 10% fetal calf serum and antibiotics. The cells were cultured under standard conditions and subjected to hypoxic shock (1% O2) in a similar manner.
Construction of the ChIP-seq library and analysis of ChIP-seq tags
DLD-1 and TIG-3 cells (1 × 108) were fixed using a final concentration of 1% formaldehyde at room temperature for 10 min. To quench the reaction, 150 mM (final concentration) glycine was added to the samples followed by a 5-min incubation. The cells were washed twice with PBS, harvested and then lysed in 5 ml of Lysis Buffer 1 (50 mM HEPES–KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100). The lysates were incubated at 4°C for 10 min and centrifuged at 1,500 rpm for 5 min at 4°C. The pellets were then resuspended in 5 ml of Lysis Buffer 2 (10 mM Tris–HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA), incubated at room temperature for 10 min, and centrifuged at 1,500 rpm for 5 min at 4°C. The pellets were resuspended in 1 ml of Lysis Buffer 3 (10 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, 0.5% N-lauroylsarcosine) and sonicated with 18 cycles of 30 s each on ice using a sonicator (TOMY SEIKO). One hundred microliters of 10% Triton-X 100 was added to the samples, and the cell lysates were centrifuged for 10 min. Fifty microliters of the supernatant was saved for the controls (named whole cell extract (WCE) DNA). Washed magnetic beads bound to 10 μg of rabbit polyclonal anti-HIF-1α antibody (Novus Biologicals, Inc., NB100-134), monoclonal anti-RNA polymerase II antibody (Abcam, ab817), monoclonal anti-H3K4me3 antibody (ab1012), polyclonal anti-H3Ac antibody (Millipore, 06-599) or monoclonal anti-H3K27me3 antibody (ab6002) was added to the supernatant. The samples were rotated at 4°C overnight and washed 8 times with 1 ml of wash buffer (50 mM HEPES–KOH, pH 7.5, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-deoxycholate) and once with TE buffer containing 50 mM NaCl. The sample was then eluted with 200 μl of elution buffer (1 M Tris–HCl, pH 8.0, 0.5 M EDTA, pH 8.0, 1% SDS) at 65°C for 15 min. The supernatant was transferred to a new tube and incubated at 65°C overnight. Concurrently, 150 μl of elution buffer was added to the saved WCE-DNA, and the samples were incubated at 65°C overnight. Next, 200 μl of TE and 8 μl of 10 mg/ml RNase A (Funakosi) were added to the IP and WCE DNA samples. The samples were then incubated at 37°C for 2 h. Subsequently, 4 μl of 20 mg/ml proteinase K (Takara) was added to the samples, which were then incubated at 55°C for 2 h. The DNA samples were purified using TRIzol LS (Invitrogen) and ethanol precipitation. Samples destined for ChIP-seq by Illumina GA were prepared according to the manufacturer’s instructions.
The generated ChIP-Seq tags were mapped to the reference human genome sequences (hg18), and the tags that were uniquely mapped allowing two-base mismatches were used. The binding sites of HIF-1α, RNA polymerase II and histone modifications, based on the short-read tag information, were identified as follows: the regions encompassed by the mapped tag sequences were extended to 120 bp, which reflected the insertion sites of the sample DNA fragments. For each genomic position, the number of overlapping extended tags was counted. Based on the calculated tag information, the sum of the included tags was evaluated to determine whether more than a tenfold difference between the immunoprecipitation (IP) and the whole cell extract (WCE) was present. Genomic regions in which positive enrichment of the tags continued for more than 121 bp were then selected. Among these regions, those containing more than 5 different sequence tags were identified as potential HIF-1α and RNA polymerase II binding sites. We normalized the tag counts for each region to tags per million (ppm) and divided the results by the length of the region (ppm/bp). These values were determined as the peak strength in this study. In the HIF-1α ChIP-Seq analysis, if the identified regions demonstrated an overlap between 1% O2 (hypoxia) and 21% O2 (normoxia), regions with more than a twofold (hypoxia/normoxia) change in peak strength were identified as “bindings enriched in hypoxia.” The statistical significance determined for this selection procedure compared to the background rate was evaluated using Poisson probabilities as previously described (Robertson et al. 2007): where P(x,λ) is the probability of enrichment, λ is the expected tag number in the 121-bp window calculated for the WCE sample, and x is the observed tag number in the 121-bp window.
To analyze the gene expression changes in the transcription factors in DLD-1 and TIG-3 cells, 140 transcription factors were selected in TRANSFAC (Rel. 2010.1). The consensus sequences of the transcription factors were also evaluated using MATCH with cutoff values determined using minFP, which minimizes false-positive results. The enrichment of the detected putative binding sites in the HIF-1α target genes in DLD-1 cells, TIG-3 cells and both cell lines were evaluated by calculating the hypergeometric distributions. Putative transcription factor binding sites that were statistically significantly enriched (P < 0.05) in the respective groups were selected. For details, see Supplementary Table 3.
TSS-Seq analysis and RNA-Seq analysis of polysome fractions
TSS-Seq tags were prepared and analyzed as described in the reference (Tsuchihara et al. 2009). After clustering the TSS-tags using 500-bp bins, representative TSSs were selected as the position from which the largest number of TSS tags was mapped. The selected representative TSSs were used for further analyses.
For the RNA-Seq analysis of polysome-incorporated RNA, the cytoplasmic fraction was isolated from DLD-1 cells using the PARIS Kit (Ambion, AM1921). Polysome-incorporated fractions were further fractionated from cytoplasmic fraction using the sucrose-density-gradient method described in the reference (Koritzinsky and Wouters 2007). Thirty-six-base-pair single-end-read RNA-Seq tags were generated using an Illumina GA sequencer according to the standard protocol. RNA-Seq tags that were mapped to the human reference genome sequences without any mismatches were used. RNA-Seq tags corresponded to RefSeq transcripts when their genomic coordinates overlapped. Details of the characterization and the RNA-Seq libraries are presented in Supplementary Fig. 6.
Construction of the nucleosome-Seq library and analysis of nucleosome tags
Cells were cultured to 80% confluence and treated with micrococcal nuclease to generate mononucleosomes using the ChIP-IT Express Enzymatic Kit (active motif). The cells were formaldehyde-cross-linked prior to the nucleosome isolation. Cross-linking was performed with fixation solution (DMEM, 1% formaldehyde) for 10 min at room temperature. The cells were then washed with PBS, and the cross-linking reaction was stopped by incubating the cells with a glycine quenching solution (PBS glycine buffer) for 5 min at room temperature. After the dishes were washed with PBS, an ice-cold cell scraping solution was added. The cells were then harvested and resuspended in ice-cold lysis buffer, incubated on ice for 30 min, and homogenized by 15–20 strokes with a Dounce homogenizer. The nuclei were suspended in digestion buffer and pre-warmed in this solution for 5 min at 37°C. An enzymatic cocktail (200 U/ml) was added to the sample, and the digestion reaction was incubated at 37°C for 15 min. After the reaction was stopped with EDTA, the nuclei were pelleted by centrifugation, and the supernatants were collected. Formaldehyde cross-linking was reversed by the addition of 5 M NaCl and RNase followed by an incubation at 65°C for more than 4 h. Proteinase K was added to the samples, and the mixtures were incubated at 42°C for 1.5 h. DNA was purified by phenol/chloroform extraction and ethanol precipitation. The extracted DNA was used for the sample preparation for Illumina GA according to the manufacturer’s instructions.
Real-time PCR analysis
Real-time PCR primers were designed within the identified HIF-1α binding sites. Primer3 (http://www.frodo.wi.mit.edu/primer3/) was used to design the primers. The fold enrichment at each locus was calculated according to the ΔΔCt method. The primer sequences are presented in Supplementary Table 1.
Results and discussion
Identification of HIF-1α binding sites
Number of HIF-1α binding sites
Hypoxia-responsive binding sites
Non-hypoxia-responsive binding sites
Total binding sites
Sites containing HRE
Using the identified “hypoxia-responsive” HIF-1α binding sites, we searched for the HRE motif. We found that 441 (83%) and 413 (67%) regions contained the HRE motif in DLD-1 and in TIG-3 cells, respectively (fourth column, Table 1). These frequencies were similar to those reported in previous HIF-1α ChIP-chip studies (Mole et al. 2009; Xia et al. 2009), although the detected genomic regions containing the HIF-1α binding sites were shorter in length due to the improved resolution of the analysis (the lengths of the detected binding sites were more than threefold shorter than those detected in previous studies using ChIP-chip, which reflected the intervals of the designed DNA probes (Mole et al. 2009); see also Supplementary Fig. 3a). Occasionally, two or three adjacent core HRE motifs were detected in a single gene, such as the genes encoding transferrin and the glucose transporter (Wenger et al. 2005). We examined the number of HRE motifs and the ChIP-Seq tag concentrations and found no correlation between them (Supplementary Fig. 3b). The HRE motif plays a role in defining the binding positions but may not contribute directly to the binding strength.
Transcripts in the proximal regions of the identified HIF-1α binding sites
To directly examine the positions of the TSSs and their expression changes in response to HIF-1α binding in DLD-1 and TIG-3 cells, we used TSS-Seq data. This dataset contains a total of 141,590,200 TSS tags, each of which corresponds to the cap site of a single mRNA (Tsuchihara et al. 2009). We clustered the TSS tags into TSS clusters (TSCs) to separate individual putative promoter units (see the reference (Tsuchihara et al. 2009) for details). The numbers of TSS tags were normalized to parts per million mapped TSS tags, and the sum of the TSS tag concentrations associated with the same TSC was defined as the expression level of the TSC. The fold changes of each TSC in response to hypoxia were evaluated as the changes in TSS tag concentrations under hypoxia versus normoxia. [The statistics obtained for the TSS tags are shown in Supplementary Fig. 4. Additional details can be also found in the reference (Tsuchihara et al. 2009).]
Target genes of HIF-1α in DLD-1 and TIG-3 cells
We compared the HIF-1α target genes in DLD-1 cells and TIG-3 cells. We found that 18 genes overlapped, and the remaining genes were unique to each cell type. We performed Gene Ontology (GO) term (Ashburner et al. 2000) analysis to examine whether the gene groups of particular functional categories were enriched in the respective cell types. Seven and four GO terms were enriched (hypergeometric distribution; P < 0.01) in DLD-1 and TIG-3 cells, respectively (see also Supplementary Tables 2a and 2b for the full list). Of these, GO term “glycolysis” (GO: 0006096) was commonly enriched. “Response to hypoxia” (GO: 0001666) was enriched only in DLD-1 cells. It was intriguing that the genes belonging to this GO term, which are considered to have indispensable roles in the maintenance of homeostasis under hypoxic conditions, were selectively enriched in DLD-1 cells (proportion test; P = 0.0001). TIG-3 cells, which represent a normal cell type and thus have never been exposed to hypoxia, may not be robust in hypoxia because several essential genes are not induced.
We also found that the hypoxic response of DLD-1 cells was more significant than that of TIG-3 cells, both in the number of target genes and in the degree of expression induced (Wilcoxon rank sum test; P = 3e–13). Figure 3c illustrates the fold expression changes in DLD-1 and TIG-3 cells.
To further characterize the molecular mechanisms underlying the differential gene expression observed between the cell types, we assessed the global expression patterns of transcription factors in DLD-1 cells and TIG-3 cells on the basis of digital TSS tag counts for the genes encoding transcription factors. We used a total of 140 well-characterized transcription factors that were registered in the representative database TRANSFAC. As shown in Supplementary Fig. 7, transcriptional induction of the transcription factor genes was more significant in DLD-1 cells than in TIG-3 cells (P = 0.02) (see also Supplementary Fig. 8 for an example). To specify the transcription factors that might be responsible for the activation of particular genes, we examined the enrichment of consensus binding sites for specific transcription factors in the surrounding regions of HIF-1α binding sites. We examined the genes which were identified as HIF-1α target genes in DLD-1 cells, TIG-3 cells or in both cell types. We found that fourteen consensus binding sequences were enriched around the HIF-1α binding sites in total. Of these sequences, four transcription factors were transcriptionally induced more than twofold in the TSS-Seq analysis in the corresponding cell types (see Supplementary Table 3 for the full list). These transcription factors may regulate the transcription of HIF-1α target genes in cooperation with HIF-1α in DLD-1 cells or TIG-3 cells. It is also interesting to speculate that the coordinated expression of the transcription factors might have been acquired throughout cellular history. DLD-1 cells originated from a solid tumor that experienced severe hypoxic conditions (Rajaganeshan et al. 2009; Schmitz et al. 2009). Similar analyses will be necessary in the future to assess a greater variety of cell types in order to validate this hypothesis.
Epigenetic regulation in regions surrounding HIF-1α binding sites
HIF-1α regulation of alternative promoter variants
Number of TSCs associated with binding sites located in genic and intergenic regions
#HIF-1α bound genes in which TSCs overlapped the 5′-end of RefSeq transcript models
#HIF-1α target genes
#Previously characterized AP TSCs (#genes)
#Newly identified AP TSCs (#genes)
#Intergenic TSCs located in repetitive regions
HIF-1α binding sites in intergenic regions
The combination of ChIP-Seq and TSS-Seq allowed us to identify HIF-1α targets even in previously unannotated (so-called “intergenic”) regions. Approximately one-third of the HIF-1α binding sites were located in regions that were >50 kb from the nearest RefSeq genes. For these intergenic binding sites, we searched for TSCs located from 1 kb upstream to 10 kb downstream of the HIF-1α binding sites and identified 262 and 105 putative HIF-1α target TSCs in DLD-1 and TIG-3 cells, respectively (Table 2). Twenty-one and 21 binding sites were located in repetitive regions (see also Supplementary Table 5), which suggested that some HIF-1α target sites might also have arose from repetitive regions, as previously reported for several transcription factors (Tomilin 2008; Polak and Domany 2006) (see Supplementary Fig. 14 for one of these examples). We also found that the distributions of the distances from HIF-1α binding sites to TSCs were similar to those determined for the HIF-1α target RefSeq genes (Supplementary Fig. 15).
We searched the completely sequenced full-length cDNAs that corresponded to these TSCs and found seven overlapping cDNAs from the FLJ (Ota et al. 2004) and MGC (Gerhard et al. 2004) cDNA collections in DLD-1 and TIG-3 cells (Supplementary Table 6a). All of the corresponding full-length cDNAs lacked clear open reading frames. We determined the complete sequences of the overlapping ESTs for an additional three cases and obtained similar results (Supplementary Table 6b). An analysis of the RNA-Seq tags in the polysome fractions also suggested that majority of these intergenic HIF-1α targets were not translated (Supplementary Fig. 6c). Therefore, the intergenic TSCs of HIF-1α targets should be used to transcribe hypoxia-responsive non-protein-coding transcripts (Wilusz et al. 2009).
To determine whether these TSCs were precursors of micro-RNAs (He and Hannon 2004), we searched for miRNAs registered in the miRBase (Griffiths-Jones et al. 2006) from 10 kb upstream to 50 kb downstream of the intergenic HIF-1α binding sites. No miRNAs were located within these regions. Furthermore, we could not detect any overlap against the previously reported repertoire of putatively-functional long non-coding RNAs (Guttman et al. 2009). We considered that these intergenic TSCs were not derived from our experimental errors, especially those identified in DLD-1 cells (Barski et al. 2007; Welboren et al. 2009), since we detected clear binding signals for pol II around 61 (21%) and 2 (2%) intergenic TSC targets of HIF-1α. These results collectively suggested that we had identified putative non-protein-coding transcript targets of HIF-1α that were comparable to the canonical RefSeq targets with respect to the number of targets and their levels of induction. However, further analyses are needed to determine the biological relevance underlying the induction of these non-coding transcripts.
In the present paper, we describe the genome-wide identification of HIF-1α binding sites in the cancerous DLD-1 cell line and the normal lung fibroblast TIG-3 cell line using ChIP-Seq. We utilized several types of Illumina GA analyses to further characterize the identified binding sites. The greatest advantages of using massively parallel sequencers may be the ability to obtain versatile biological data. In fact, we were able to obtain extensive biological information that allowed us to interpret the binding events; such information could not have been obtained using ChIP-chip or microarray analysis alone. We unexpectedly discovered that HIF-1α binding sites regulate an unexpectedly large population of alternative promoters and putative non-coding transcripts. These categories of the transcripts may also contribute to hypoxic response of the cell, though they have been overlooked in previous studies. The analyses targeting these transcripts were first enabled by the single-base resolution of massively parallel sequencing technologies, for which no previous knowledge was necessary for the probe design.
An obvious limitation of the present study was the use of only two cell types. Thus, we could not identify all of the possible binding sites of HIF-1α. The identification of different targets in DLD-1 and TIG-3 cells indicates that similar analyses should be conducted using a wider variety of cell types. In addition, our stringent criteria may have precluded the identification of many genuine targets. Indeed, some genes that have been well characterized as HIF-1α target genes were not found in our study, including the telomerase (TERT) gene (Nishi et al. 2004), the vascular endothelial growth factor A (VEGFA) gene (Carmeliet et al. 1998; Forsythe et al. 1996) and the erythropoietin gene (Semenza and Wang 1992) [also note that this result is similar to that obtained in a previous ChIP-chip analysis (Mole et al. 2009)].
All of the data generated in the present study were essentially the sequence data; however, we believe that the applications of massive sequencing at various biological levels have yielded substantial biological indications. We could find that the epigenetic regulation of chromatin status and the differential repertoires of expressed transcription factors played essential roles in the cell-type-specific induction of target genes in DLD-1 and TIG-3 cells in response to hypoxia. Further extensive analyses of epigenetic changes in cancer and normal cells using Nucleosome-Seq and ChIP-Seq and of the expression patterns of transcriptions factors using TSS-Seq or RNA-Seq could reveal the mechanisms by which the differential responses of various cells to hypoxia are encoded. Such information could reveal how hypoxic cellular responses are mediated by HIF-1α in a wide variety of cancer cells.
- Albert I, Mavrich TN, Tomsho LP, Qi J, Zanton SJ, Schuster SC, Pugh BF (2007) Translational and rotational settings of H2A.Z nucleosomes across the Saccharomyces cerevisiae genome. Nature 446:572–576View ArticlePubMedGoogle Scholar
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet 25(1):25View ArticlePubMed CentralPubMedGoogle Scholar
- Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K (2007) High-resolution profiling of histone methylations in the human genome. Cell 129(4):823–837View ArticlePubMedGoogle Scholar
- Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ (2009) An integrative genomics approach identifies hypoxia inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 37(14):4587–4602View ArticlePubMed CentralPubMedGoogle Scholar
- Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394(6692):485–490View ArticlePubMedGoogle Scholar
- Davuluri RV, Suzuki Y, Sugano S, Plass C, Huang TH (2008) The functional consequences of alternative promoter use in mammalian genomes. Trends Genet 24(4):167–177View ArticlePubMedGoogle Scholar
- Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16(9):4604–4613View ArticlePubMed CentralPubMedGoogle Scholar
- Fraisl P, Aragones J, Carmeliet P (2009) Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 8(2):139–152View ArticlePubMedGoogle Scholar
- Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane TJ, Hill RP (1998) Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48(2):149–156View ArticlePubMedGoogle Scholar
- Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891–899View ArticlePubMedGoogle Scholar
- Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res 14(10B):2121–2127Google Scholar
- Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ (2006) miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34(Database issue):D140–D144View ArticlePubMed CentralPubMedGoogle Scholar
- Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458(7235):223–227View ArticlePubMed CentralPubMedGoogle Scholar
- Harris AL (2002) Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47View ArticlePubMedGoogle Scholar
- He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5(7):522–531View ArticlePubMedGoogle Scholar
- Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, Van Calcar S, Qu C, Ching KA, Wang W, Weng Z, Green RD, Crawford GE, Ren B (2007) Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 39(3):311–318View ArticlePubMedGoogle Scholar
- Hirota K, Semenza GL (2006) Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 59(1):15–26View ArticlePubMedGoogle Scholar
- Jiang C, Pugh BF (2009) Nucleosome positioning and gene regulation: advances through genomics. Nat Rev Genet 10(3):161–172View ArticlePubMedGoogle Scholar
- Keith B, Simon MC (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129(3):465–472View ArticlePubMed CentralPubMedGoogle Scholar
- Kim J, Chu J, Shen X, Wang J, Orkin SH (2008) An extended transcriptional network for pluripotency of embryonic stem cells. Cell 132(6):1049–1061View ArticlePubMedGoogle Scholar
- Koritzinsky M, Wouters BG (2007) Hypoxia and regulation of messenger RNA translation. Methods Enzymol 435:247–273View ArticlePubMedGoogle Scholar
- Kwon H, Thierry-Mieg D, Thierry-Mieg J, Kim HP, Oh J, Tunyaplin C, Carotta S, Donovan CE, Goldman ML, Tailor P, Ozato K, Levy DE, Nutt SL, Calame K, Leonard WJ (2009) Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 31(6):941–952View ArticlePubMed CentralPubMedGoogle Scholar
- Landry JR, Mager DL, Wilhelm BT (2003) Complex controls: the role of alternative promoters in mammalian genomes. Trends Genet 19(11):640–648View ArticlePubMedGoogle Scholar
- Lin B, Wang J, Hong X, Yan X, Hwang D, Cho JH, Yi D, Utleg AG, Fang X, Schones DE, Zhao K, Omenn GS, Hood L (2009) Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One 4(8):e6589View ArticlePubMed CentralPubMedGoogle Scholar
- Maxwell PH (2005) The HIF pathway in cancer. Semin Cell Dev Biol 16(4–5):523–530View ArticlePubMedGoogle Scholar
- Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, Ratcliffe PJ (2009) Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 284(25):16767–16775View ArticlePubMed CentralPubMedGoogle Scholar
- Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K (2004) Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol 24(13):6076–6083View ArticlePubMed CentralPubMedGoogle Scholar
- Nordsmark M, Overgaard M, Overgaard J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41(1):31–39View ArticlePubMedGoogle Scholar
- Ortiz-Barahona A, Villar D, Pescador N, Amigo J, del Peso L (2010) Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucleic Acids Res 38(7):2332–2345View ArticlePubMed CentralPubMedGoogle Scholar
- Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet 36(1):40–45Google Scholar
- Park PJ (2009) ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet 10(10):669–680View ArticlePubMed CentralPubMedGoogle Scholar
- Polak P, Domany E (2006) Alu elements contain many binding sites for transcription factors and may play a role in regulation of developmental processes. BMC Genomics 7:133View ArticlePubMed CentralPubMedGoogle Scholar
- Poon E, Harris AL, Ashcroft M (2009) Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 11:e26View ArticlePubMedGoogle Scholar
- Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441(7092):437–443View ArticlePubMedGoogle Scholar
- Rajaganeshan R, Prasad R, Guillou PJ, Scott N, Poston G, Jayne DG (2009) Expression patterns of hypoxic markers at the invasive margin of colorectal cancers and liver metastases. Eur J Surg Oncol 35(12):1286–1294View ArticlePubMedGoogle Scholar
- Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25(13):5675–5686View ArticlePubMed CentralPubMedGoogle Scholar
- Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T, Euskirchen G, Bernier B, Varhol R, Delaney A, Thiessen N, Griffith OL, He A, Marra M, Snyder M, Jones S (2007) Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods 4(8):651–657View ArticlePubMedGoogle Scholar
- Schmitz KJ, Muller CI, Reis H, Alakus H, Winde G, Baba HA, Wohlschlaeger J, Jasani B, Fandrey J, Schmid KW (2009) Combined analysis of hypoxia-inducible factor 1 alpha and metallothionein indicates an aggressive subtype of colorectal carcinoma. Int J Colorectal Dis 24(11):1287–1296View ArticlePubMedGoogle Scholar
- Schones DE, Cui K, Cuddapah S, Roh TY, Barski A, Wang Z, Wei G, Zhao K (2008) Dynamic regulation of nucleosome positioning in the human genome. Cell 132(5):887–898View ArticlePubMedGoogle Scholar
- Semenza GL (2000) HIF-1 and human disease: one highly involved factor. Genes Dev 14(16):1983–1991PubMedGoogle Scholar
- Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732View ArticlePubMedGoogle Scholar
- Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29(5):625–634View ArticlePubMed CentralPubMedGoogle Scholar
- Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12(12):5447–5454View ArticlePubMed CentralPubMedGoogle Scholar
- Thomas JD, Johannes GJ (2007) Identification of mRNAs that continue to associate with polysomes during hypoxia. Rna 13(7):1116–1131View ArticlePubMed CentralPubMedGoogle Scholar
- Tian H, McKnight SL, Russell DW (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11(1):72–82View ArticlePubMedGoogle Scholar
- Tomilin NV (2008) Regulation of mammalian gene expression by retroelements and non-coding tandem repeats. Bioessays 30(4):338–348View ArticlePubMedGoogle Scholar
- Tsuchihara K, Suzuki Y, Wakaguri H, Irie T, Tanimoto K, Hashimoto S, Matsushima K, Mizushima-Sugano J, Yamashita R, Nakai K, Bentley D, Esumi H, Sugano S (2009) Massive transcriptional start site analysis of human genes in hypoxia cells. Nucleic Acids Res 37(7):2249–2263View ArticlePubMed CentralPubMedGoogle Scholar
- Valouev A, Johnson DS, Sundquist A, Medina C, Anton E, Batzoglou S, Myers RM, Sidow A (2008) Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. Nat Methods 5(9):829–834View ArticlePubMed CentralPubMedGoogle Scholar
- Wang GL, Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270(3):1230–1237View ArticlePubMedGoogle Scholar
- Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, Stunnenberg HG (2009) ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J 28(10):1418–1428View ArticlePubMed CentralPubMedGoogle Scholar
- Wenger RH, Kvietikova I, Rolfs A, Camenisch G, Gassmann M (1998) Oxygen-regulated erythropoietin gene expression is dependent on a CpG methylation-free hypoxia-inducible factor-1 DNA-binding site. Eur J Biochem 253(3):771–777View ArticlePubMedGoogle Scholar
- Wenger RH, Stiehl DP, Camenisch G (2005) Integration of oxygen signaling at the consensus HRE. Sci STKE (306):re12Google Scholar
- Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt KU (2003) Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. Faseb J 17(2):271–273PubMedGoogle Scholar
- Wilusz JE, Sunwoo H, Spector DL (2009) Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 23(13):1494–1504View ArticlePubMed CentralPubMedGoogle Scholar
- Xia X, Kung AL (2009) Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. Genome Biol 10(10):R113View ArticlePubMed CentralPubMedGoogle Scholar
- Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS, Kung AL (2009) Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A 106(11):4260–4265View ArticlePubMed CentralPubMedGoogle Scholar
- Zhang Y, Moqtaderi Z, Rattner BP, Euskirchen G, Snyder M, Kadonaga JT, Liu XS, Struhl K (2009) Intrinsic histone-DNA interactions are not the major determinant of nucleosome positions in vivo. Nat Struct Mol Biol 16(8):847–852View ArticlePubMed CentralPubMedGoogle Scholar